Last reviewed · How we verify
methylprednisolone PO
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus), Allergic reactions and asthma exacerbations, Adrenal insufficiency.
At a glance
| Generic name | methylprednisolone PO |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General anti-inflammatory |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone is a synthetic glucocorticoid that exerts its anti-inflammatory and immunosuppressive effects by binding to intracellular glucocorticoid receptors, translocating to the nucleus, and modulating gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. It is commonly used orally (PO) for a wide range of inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- Allergic reactions and asthma exacerbations
- Adrenal insufficiency
- Certain hematologic malignancies and lymphomas
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia / glucose intolerance
- Hypertension
- Insomnia and mood changes
- Increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
- Cushingoid features (with chronic use)
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methylprednisolone PO CI brief — competitive landscape report
- methylprednisolone PO updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI